We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. markets closed

Novan, Inc. (NOVN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
8.56+0.11 (+1.30%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inside Bar (Bullish)

Inside Bar (Bullish)

Previous Close8.45
Open8.40
Bid8.53 x 900
Ask8.56 x 800
Day's Range8.25 - 8.58
52 Week Range4.33 - 25.90
Volume174,715
Avg. Volume783,926
Market Cap161.041M
Beta (5Y Monthly)-0.03
PE Ratio (TTM)N/A
EPS (TTM)-2.06
Earnings DateOct 28, 2021 - Nov 01, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est42.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Novan, Inc.
    EGRX: Lowering target price to $42.00EAGLE PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $42.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • GlobeNewswire

    Novan Announces Strategic Priorities and Outlines Key Milestones

    – Company planning for three potential New Drug Application (NDA) filings in three years with the first submission expected in Q3 2022 for lead program SB206 in molluscum contagiosum – – Late-stage product candidate, SB204 for the treatment of acne vulgaris, selected to advance as second lead program toward pivotal Phase 3 study – – SB019 SARS-CoV-2 development program advancing toward Phase 1 study in healthy volunteers, targeted for 1H 2022 – – Company to host conference call and webcast today

  • GlobeNewswire

    Novan Engages Syneos Health as Commercial Solutions Provider for SB206

    – Company targeting New Drug Application (NDA) for SB206 in Q3 2022, following recent clinically and statistically significant topline efficacy results from a pivotal Phase 3 B-SIMPLE4 trial in patients with molluscum contagiosum – – Syneos Health provides immediate access to commercial infrastructure with deep dermatology expertise and a track record of success – DURHAM, N.C., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its selection

  • GlobeNewswire

    Novan to Present at H.C. Wainwright 23rd Annual Global Investment Conference

    DURHAM, N.C., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will participate in a fireside chat during the September 13th – 15th H.C. Wainwright 23rd Annual Global Investment Conference. In addition to the fireside chat, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered t

  • GlobeNewswire

    Novan to Host Corporate Update Conference Call and Webcast on September 9, 2021

    – Conference call with live audio webcast to be held on Thursday, September 9th at 8:30 a.m. ET – DURHAM, N.C., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Novan management will host a corporate update conference call with live audio webcast on Thursday, September 9, 2021 at 8:30 a.m. ET. The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the N

  • GlobeNewswire

    Novan Appoints Tomoko Maeda-Chubachi, MD, PhD, MBA as Chief Medical Officer

    – Dr. Maeda-Chubachi, who served as Novan’s Senior Vice President, Medical has played a key role in the design and execution of the Company’s development programs – – Dr. Maeda-Chubachi was instrumental in the execution of B-SIMPLE4, the Company’s pivotal Phase 3 trial of SB206 in molluscum contagiosum, which recently reported positive topline efficacy and safety results – – Additionally, the Company announces Dr. Maeda-Chubachi’s publication in JID Innovations based on previously completed Phas

  • Zacks Small Cap Research

    NOVN: Hard to Top Novan’s Big June: Study Readouts, Capital Raise & Russell Inclusion

    By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT Second Quarter 2021 Results On August 12, 2021, Novan Inc. (NASDAQ:NOVN) reported second quarter financial results in a press release concurrent with the filing of Form 10-Q . A conference call and webcast with supporting presentation was also held to update investors on financial and operational results. The period included

  • GlobeNewswire

    Novan Reports Second Quarter 2021 Financial Results and Provides Corporate Update

    – Positive data across all three of the Company’s priority pipeline development programs, announced in Q2 2021, further validating the potential of its novel, proprietary NITRICIL™ technology – – Preparation underway for the Company's first New Drug Application filing for lead program, SB206, following the statistically significant topline efficacy results from pivotal Phase 3 trial in patients with molluscum contagiosum – – Ongoing exploration of opportunities for pipeline expansion and clinica

  • GlobeNewswire

    Novan to Report Second Quarter 2021 Financial Results on August 12, 2021

    Company to host conference call and webcast on Thursday, August 12, 2021, at 8:30 a.m. ETDURHAM, N.C., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its second quarter 2021 financial results on Thursday, August 12th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day. The call will be led by Paula Brown Stafford, President

  • GlobeNewswire

    Novan Announces Last Patient Visit at Week 24 in B-SIMPLE4 Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum

    – Company previously reported positive topline efficacy and favorable safety data at Week 12 from B-SIMPLE4 in June 2021, with primary endpoint achieving statistical significance with p-value less than 0.0001 and no serious adverse events related to treatment with SB206 – – Planned follow-up visit at week 24 is intended to further evaluate safety of SB206, 12 weeks following patient completion of treatment, with results expected in Q3 2021 – – Novan intends to submit New Drug Application (“NDA”)

  • GlobeNewswire

    Novan Announces Inclusion in Russell Microcap® Index

    DURHAM, N.C., June 24, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that as part of the annual reconstitution of the Russell stock indexes, Novan has been selected to join the Russell Microcap® Index, effective after the U.S. market close on June 25, 2021, according to the list of additions published by FTSE Russell as of June 4, 2021. “This is truly an exciting time for Novan, on multiple fronts. On the heels of our recently announced positive